GHRP-6 timeline: what research and user reports show

GHRP-6 was one of the first growth-hormone releasing peptides studied, and it comes with a side effect that newer, more selective secretagogues like Ipamorelin were specifically designed to avoid: a noticeable rise in appetite.

Early doses: appetite and hunger

Increased hunger, sometimes described as fairly strong, is the most consistently reported effect starting from the first doses. This is tied to GHRP-6 acting on the ghrelin receptor, the same receptor that drives natural hunger signaling.

Weeks 1 to 2: sleep and injection-site notes

Better sleep is commonly reported in this window, alongside mild injection-site reactions or occasional water retention.

Weeks 3 to 12: slower changes

Recovery and body-composition changes are reported to build gradually, similar to other secretagogues in this class, though the appetite effect is generally described as the more immediately noticeable feature of GHRP-6 specifically.

Common questions

Why does GHRP-6 increase appetite more than Ipamorelin? It is less selective for the ghrelin receptor pathway and is reported to stimulate hunger signaling more strongly, which is part of why newer secretagogues were developed.

For mechanism, dosing reference and citations, see the GHRP-6 reference page.